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ABSTRACT
Cyclosporine elimination in a regimen including sirolimus has been shown to be a safe and
effective approach to improve graft function. Nevertheless, it is still unknown whether the
functional benefit of CyA withdrawal coincides with a subsequent reduction in histologic
lesions of chronic damage or development of chronic allograft nephropathy. This
consideration would forcast a reduction in the rate of long-term graft loss. We analyzed
114 graft biopsies from a subgroup of 57 patients that had been included in a randomized
study to eliminate CyA at 3 months posttransplant from a regimen including sirolimus
either in group A CyA SRL vs group B of SRL with CyA elimination at 3 months. Every
patient had two biopsies, one at transplantation and another at 1 year. The biopsy reading
was performed in a blinded manner by a central pathologist using the Banff 1997 and the
CADI classifications. A significantly lower rate of progression of tubular and interstitial
chronic lesions between basal and 1-year biopsies was observed for group B patients. In
addition, the incidence of new cases of chronic allograft nephropathy during the first year
was significantly lower in the group in which CyA had been eliminated at 3 months
posttransplant. We conclude that early elimination of CyA in the first months posttrans-
plant, when SRL is used as the main immunosuppressant, reduces the appearance or
worsening of chronic histologic lesions, probably as a consequence of long-term CyA
toxicity prevention.
CHRONIC ALLOGRAFT NEPHROPATHY (CAN)is the main cause of graft loss after the first year of
transplantation with a prevalence of about 60% to 70%
among protocol biopsies performed at 2 years posttrans-
plant in patients receiving the calcineurin inhibitors cyclo-
sporine (CyA) or tacrolimus (TRC).1 These drugs seem to
play a role in the development of CAN and subsequent
attenuation of long-term graft survival due to their neph-
rotoxic effects.2 Sirolimus (SRL) has shown similar efficacy
to CsA when used alone with respect to graft rejection rates
and short-term graft survival, whether combined with ste-
roids and azathioprine or steroids and mycophenolate
mofetil (MMF).3,4 A low rejection rate and minimization of
CyA nephrotoxicity at 3 years were demonstrated in multi-
center, randomized, phase III trial currently ongoing at 57
centers in Europe, Canada, and Australia, including 525
patients. The trial compares a control arm (A) using CyA,
fixed doses of SRL, and steroids, and an study arm (B) with
concentration-controlled SRL and steroids with suspension
of CyA at 3 months posttransplant.5 Using a substudy of
this trial, including 70 patients in the ten centers participat-
ing in Spain and Portugal, we hypothesized a lower rate of
progression of chronic allograft pathologic lesions when
CyA was eliminate based upon a retrospective analysis of
the information supplied by ten local pathologists.6 Herein
we present the results of a prospective reanalysis of the
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renal biopsies of this subgroup of patients by a central,
blinded pathologist.
MATERIALS AND METHODS
One hundred fourteen graft biopsies corresponding to 57 of the
subgroup of 70 patients (81%) reported in our previous article6
were reevaluated by a central pathologist (J.M.G.) in a blinded
manner. Every patient had both a pretransplant (basal) and a
1-year biopsy. Twenty-nine cases had been included in group A
(CyA  SRL) and 28 in group B (SRL with CyA withdrawal at 3
months post-Tx). Biopsies were reevaluated according to the Banff
1997 and CADI classifications. Both groups were compared for
every individual lesion. Three chronicity scores (CS) were calcu-
lated as the sum of the chronic items (Banff CS1: cg ci ct cv;
Banff CS2: cg  ci  ct  cv  ah; and CADI CS: i  f  m  g
 t  v). Differences in renal function at 1 year were reported in
a previous study.6 We considered the presence of progression when
any given Banff or CADI code was higher in the 1-year biopsy than
in the transplant (basal) biopsy; when it was equal or lower it was
considered nonprogression. Chronicity scores were analyzed in the
same way. The percentage of patients with progression of chronic-
ity findings in every group (individual lesions and CS) was com-
pared using the chi-square test. We also calculated the prevalence
of CAN (diagnosed according to Banff 1997 criteria) at the
moment of transplantation versus 1 year, and the incidence of new
cases of this entity that developed during the first year (patients
with absence in basal biopsy and presence of CAN at 1 year) in
every group.
RESULTS
The progression rates of Banff chronic lesions for patients
in groups A and B, respectively, were: cg, 0% vs 9.1%; ci,
70% vs 40.9%; ct, 70% vs 47.8%; cv, 29.4% vs 25%; and ah,
10.5% vs 19%, whereas progression rates of CADI lesions
were: i, 52.6% vs 54.5%; f, 68.4% vs 40.9%; m, 21.1% vs
23.8%; g, 5.3% vs 14.3%; t, 68.4% vs 45.5%; and v, 31.3%
vs 23%. When CS were considered the following rates of
progression were observed: Banff CS1, 76.5% vs 31.3% (P
 .05); Banff CS2, 76.5% vs 37.5% (P  .05); and CADI-
CS, 75% vs 43.8%. The prevalence of CAN at 1 year was
higher in group A (70.8% vs 59.3%; P NS) despite higher
scores in group B at the time of transplantation (9.5% vs
21.7%). For this reason, the incidence of new cases of CAN
during the first year was significantly higher in group A
(65%) when compared with group B (30.8% of patients; P
 .05).
DISCUSSION
Early cyclosporine withdrawal using sirolimus is followed
not only by an improvement in renal function, but also by a
reduction in the rate of progression of chronic pathologic
allograft lesions and in the appearance of new cases of
CAN. This effect is especially important in the case of
tubular and interstitial lesions, probably as a consequence
of a reduction of CyA nephrotoxicity without an increase in
the immunologic response against the allograft. It is possi-
ble that this beneficial effect might be responsible for better
graft outcome after longer follow-up periods.
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